<div class="floatDisplay"><div class="table-wrap" id="tbl1">
<table>
<caption tabindex="0">
<span class="label">Table 1</span><span>Baseline Demographics and Disease Characteristics of Patients in the OCTAVE Induction 1 and 2 Trials</span>
</caption>
<tbody>
<tr>
<th scope="col"></th>
<th scope="col">Placebo (n = 234)</th>
<th scope="col">Tofacitinib 10 mg BID (n = 905)</th>
</tr>
<tr>
<td>Male</td>
<td>132 (56.4)</td>
<td>536 (59.2)</td>
</tr>
<tr>
<td>Age, y</td>
<td>41.1 ± 14.4</td>
<td>41.2 ± 13.8</td>
</tr>
<tr>
<th scope="row">Geographic region</th>
<td></td>
<td></td>
</tr>
<tr>
<td> Europe</td>
<td>135 (57.7)</td>
<td>534 (59.0)</td>
</tr>
<tr>
<td> North America</td>
<td>53 (22.6)</td>
<td>187 (20.7)</td>
</tr>
<tr>
<td> Other</td>
<td>46 (19.7)</td>
<td>184 (20.3)</td>
</tr>
<tr>
<td>Duration of disease, y</td>
<td>8.1 ± 7.0</td>
<td>8.1 ± 7.0</td>
</tr>
<tr>
<td>Total Mayo score</td>
<td>9.0 ± 1.5</td>
<td>9.0 ± 1.4</td>
</tr>
<tr>
<th scope="row">Stool frequency subscore</th>
<td>2.5 ± 0.7</td>
<td>2.5 ± 0.7</td>
</tr>
<tr>
<td> 0</td>
<td>0/233 (0.0)</td>
<td>14/903 (1.6)</td>
</tr>
<tr>
<td> ≤1</td>
<td>26/233 (11.2)</td>
<td>109/903 (12.1)</td>
</tr>
<tr>
<th scope="row">Rectal bleeding subscore</th>
<td>1.6 ± 0.6</td>
<td>1.6 ± 0.6</td>
</tr>
<tr>
<td> 0<a href="#title-footnote-tbl1fna" id="back-title-footnote-tbl1fna" class="figureLink"><sup>a</sup></a><span class="crossref-label" style="display: none;"></span>
</td>
<td>4/233 (1.7)</td>
<td>18/903 (2.0)</td>
</tr>
<tr>
<td> ≤1</td>
<td>103/233 (44.2)</td>
<td>380/903 (42.1)</td>
</tr>
<tr>
<td>Daily bowel movements</td>
<td>7.9 ± 3.9</td>
<td>7.9 ± 4.1</td>
</tr>
<tr>
<td> Median (range)</td>
<td>7.0 (2.0–23.0)</td>
<td>7.0 (1.0–40.0)</td>
</tr>
<tr>
<th scope="row">CRP</th>
<td></td>
<td></td>
</tr>
<tr>
<td> ≤6 mg/L</td>
<td>127 (54.5)</td>
<td>510 (57.2)</td>
</tr>
<tr>
<td> &gt;6 mg/L</td>
<td>106 (45.5)</td>
<td>381 (42.8)</td>
</tr>
<tr>
<th scope="row">Oral corticosteroid use at baseline</th>
<td>113 (48.3)</td>
<td>412 (45.5)</td>
</tr>
<tr>
<td> Mean dose<a href="#title-footnote-tbl1fnb" id="back-title-footnote-tbl1fnb" class="figureLink"><sup>b</sup></a><span class="crossref-label" style="display: none;"></span>
</td>
<td>16.5 ± 6.0</td>
<td>16.1 ± 6.4</td>
</tr>
<tr>
<td> Median dose (range)<a href="#title-footnote-tbl1fnb" id="back-title-footnote-tbl1fnb" class="figureLink"><sup>b</sup></a><span class="crossref-label" style="display: none;"></span>
</td>
<td>20.0 (5.0–25.0)</td>
<td>20.0 (2.0–30.0)</td>
</tr>
<tr>
<td>Prior anti-TNF treatment</td>
<td>130 (55.6)</td>
<td>488 (53.9)</td>
</tr>
<tr>
<td>Prior anti-TNF failure</td>
<td>124 (53.0)</td>
<td>465 (51.4)</td>
</tr>
<tr>
<td>Prior immunosuppressant failure<a href="#title-footnote-tbl1fnc" id="back-title-footnote-tbl1fnc" class="figureLink"><sup>c</sup></a><span class="crossref-label" style="display: none;"></span>
</td>
<td>158 (67.5)</td>
<td>661 (73.0)</td>
</tr>
</tbody>
</table>
<a href="javascript:void(0)" class="tableLink" onclick="window.open('/action/showFullTableImage?isHtml=true&amp;tableId=tbl1&amp;pii=S1542356518307092', '_blank')">
                        View Table in HTML
                    </a><div class="footnote">
<p>NOTE. Values are n (%), mean ± SD, or n/N (%), unless otherwise indicated.</p>
<p>BID, twice daily; CRP, C-reactive protein; N, number of evaluable patients; n, number of patients; TNF, tumor necrosis factor.</p>
</div>
<div class="footnote" id="tbl1fna">
<a href="#back-tbl1fna">a</a>The
 22 patients with rectal bleeding subscore = 0 at baseline were 
protocol deviations as patients were required to have a rectal bleeding 
subscore ≥1 at baseline.</div>
<div class="footnote" id="tbl1fnb">
<a href="#back-tbl1fnb">b</a>Mean
 and median corticosteroid doses are at day 1 of the studies and are 
expressed as prednisone equivalent dose, excluding patients taking 
budesonide or beclomethasone.</div>
<div class="footnote" id="tbl1fnc">
<a href="#back-tbl1fnc">c</a>Immunosuppressants
 included agents such as azathioprine and 6-mercaptopurine, and did not 
include biologic agents or corticosteroids.</div>
</div></div>